Illumina Launches NextSeq 1000 and 2000 Sequencing Systems with Integrated TruSight Software Suite

At the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, Francis deSouza, Global President of Illumina, announced a non-exclusive collaboration with Roche, a global leader in diagnostics. This partnership aims to accelerate the clinical accessibility of next-generation sequencing (NGS) in vitro diagnostic tests based on Illumina’s diagnostic sequencing systems. Leveraging their complementary strengths, Roche and Illumina will jointly develop new companion diagnostic methods to supplement the TruSight Oncology 500 (TSO 500) comprehensive cancer genomic profiling assay. For more details, please visit the Illumina News Center to read the full press release.

To meet the growing demand for clinical-grade genomic information while reducing testing costs, Illumina has launched the NextSeq™ 1000 and NextSeq 2000 sequencing systems. This series of sequencing systems features breakthrough system design, innovative chemistry, and an on-board bioinformatics accelerator for rapid secondary analysis. The new sequencing systems incorporate more than 75 technological innovations, including unprecedented super-resolution and innovative chemistry, which significantly increase sequencing density and throughput while lowering operational costs.

Omead Ostadan, Senior Vice President of Marketing and Products at Illumina, stated, “We are proud to continue driving down costs without compromising accuracy. The NextSeq 1000 and 2000 are designed to enable more core laboratories, small and mid-sized research laboratories, and clinical research laboratories to leverage our industry-leading SBS technology for high-throughput sequencing.”

Illumina also announced that it is developing a high-throughput NovaSeq system pursuing regulatory approval to meet the industry’s growing demand for clinical diagnostic platforms and support high-throughput, high-depth sequencing applications. The NovaSeq Dx is planned for market launch in 2022, further expanding Illumina’s Dx product portfolio. Prior to this, Illumina will collaborate with IVD partners, including Roche, to co-develop multiple applications on the NovaSeq Dx platform.

“At Illumina, we focus on three key areas to expand the reach and impact of genomics: enabling breakthrough genomic research, accelerating the clinical application of genomics, and fundamentally driving technological innovation,” said Francis deSouza, CEO of Illumina. “The NextSeq 1000 and 2000 sequencing systems, TruSight software, and our partnership with Roche will help more people access sequencing technologies, contributing to human well-being as well as scientific and clinical research.”

One-click data analysis solutions will further promote and accelerate clinical adoption. TruSight Software Suite v1.0 provides an out-of-the-box infrastructure that fully unlocks and realizes the potential of genomic sequencing in diagnosing rare and undiagnosed genetic disorders. The TruSight software streamlines and simplifies the entire workflow from sample to report, delivering valuable insights through accurate sequencing and comprehensive mutation type analysis, thereby maximizing diagnostic efficiency.

About the NextSeq 1000 and NextSeq 2000

The NextSeq 1000 and NextSeq 2000 feature a completely new design aimed at simplifying workflows and overcoming the challenges commonly faced by users of mid-throughput sequencers. By combining proven sequencing-by-synthesis (SBS) chemistry with ultra-high-resolution optics, ultra-high-density flow cells, and versatile bioinformatics solutions, the NextSeq 1000 and NextSeq 2000 have become Illumina’s most flexible sequencing systems to date. Laboratories of any size can now perform high-frequency sequencing more easily and affordably.

To create a more user-friendly end-to-end experience, the NextSeq 1000 and NextSeq 2000 are the first Illumina sequencing platforms with integrated DRAGEN. This design offers both cloud-based and on-premises configurations, providing great flexibility and convenience for run setup, project management, and data analysis. The unique combination of powerful instrument performance and cost-effective runs balances sequencing speed, quality, and cost, making this series the ideal choice for supporting emerging applications such as single-cell RNA-seq, ctDNA, and various oncology testing applications. The NextSeq 2000 and NextSeq 1000 are the first systems to adopt this new architecture. Please visit the Illumina official website to pre-order the NextSeq 2000; shipments will begin in the first quarter of 2020. The NextSeq 1000 system will begin shipping in the fourth quarter of 2020.

For Research Use Only. Not for use in diagnostic procedures.

About Illumina

Illumina is dedicated to improving human health through the power of genomics. Our focus on innovation has established us as a global leader in DNA sequencing and array technologies, serving customers across research, clinical, and applied markets. Our products are utilized in life sciences, oncology, reproductive health, agriculture, and other emerging sectors. Visit www.illumina.com.cn for more information.

Forward-Looking Statements

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on current expectations and include descriptions of known and unknown risks, including factors that could cause delays, shifts, or changes, as well as factors that could cause actual results to differ materially from current expectations. Important factors that could cause actual results to differ materially from the forward-looking statements include: (i) changes in the growth rates of the markets we serve; (ii) the volume, timing, and mix of customer orders for our products and services; (iii) our ability to manufacture instruments and consumables; (iv) the success of competing products and services; (v) inherent challenges in developing, manufacturing, and launching new products and services, including scaling or modifying manufacturing operations and reliance on third-party suppliers for critical components; (vi) the impact of recently launched or previously announced products and services on existing products and services; (vii) our ability to further develop and commercialize instruments and consumables, deploy new products, services, and applications for our technology platforms, and expand into new markets; (viii) our ability to obtain regulatory approvals for our products from government agencies; (ix) our ability to successfully collaborate with other companies and organizations to develop new products, expand into new markets, and grow our business; (x) our ability to successfully identify and integrate acquired technologies, products, and businesses; and (xi) the application of generally accepted accounting principles, which are complex and involve many subjective assumptions, estimates, and judgments, as well as other factors detailed in our filings with the U.S. Securities and Exchange Commission, including our most recent Forms 10-K and 10-Q, or information disclosed in public conference calls, the dates and times of which have been previously released. We have no obligation and do not intend to update these forward-looking statements, nor do we undertake to evaluate or confirm analysts’ related expectations or provide interim reports or updates for the current quarter.